AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32727474 — intervention group
Group type: EXPERIMENTAL
Intervention: Religion
Number of subjects: 383
Study 32727474 — intervention group
Group type: EXPERIMENTAL
Intervention: Possession of own birth certificate
Number of subjects: 383
Study 32940568 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centered lifestyle intervention
Number of subjects: 0
Study 34880372 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% gelatin solution (30 ml/kg) in group A (n=21)
Number of subjects: 64
Study 34880372 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% gelatin solution (15 ml/kg) in group B (n=21)
Number of subjects: 64
Study 34880372 — intervention group
Group type: COMPARATOR
Intervention: Isotonic multi-electrolyte solution in control group C (n=22)
Number of subjects: 64
Study 36135031 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary strength program (3 sessions per week for 8 weeks)
Number of subjects: 21
Study 36135031 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementary strength program)
Number of subjects: 21
Study 34670228 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-fraction stereotactic radiosurgery (SRS)
Number of subjects: 50
Study 34419414 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (0.5 mg three times daily for 14 days, increased to 1.0 mg tid for the subsequent 14 days)
Number of subjects: 21
Study 34419414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 32233007 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency-assisted subcision (rSubcision)
Number of subjects: 21
Study 32233007 — intervention group
Group type: COMPARATOR
Intervention: Conventional subcision
Number of subjects: 21
Study 35289915 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF prophylaxis with FOLFIRINOX
Number of subjects: 498
Study 35289915 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF prophylaxis with FOLFIRI/nab-paclitaxel
Number of subjects: 498
Study 35289915 — intervention group
Group type: COMPARATOR
Intervention: Full dose-intensity (DI) in FOLFIRINOX group
Number of subjects: 498
Study 35289915 — intervention group
Group type: COMPARATOR
Intervention: Full dose-intensity (DI) in FOLFIRI/nab-paclitaxel group
Number of subjects: 498
Study 33879569 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-large high-density lipoproteins (XL.HDL)
Number of subjects: 0
Study 33879569 — intervention group
Group type: EXPERIMENTAL
Intervention: XL.HDL.FC
Number of subjects: 0
Study 33879569 — intervention group
Group type: EXPERIMENTAL
Intervention: XL.HDL.C
Number of subjects: 0
Study 33879569 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein acetyls (GP)
Number of subjects: 0
Study 35816900 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent calorie restriction (100% of calorie needs on 5 days/week and 25% on 2 days/week)
Number of subjects: 36
Study 35816900 — intervention group
Group type: COMPARATOR
Intervention: Daily calorie restriction (78% of calorie needs 7 days/week)
Number of subjects: 36
Study 35816900 — intervention group
Group type: COMPARATOR
Intervention: Control diet (100% of calorie needs 7 days/week)
Number of subjects: 36
Study 33768223 — intervention group
Group type: EXPERIMENTAL
Intervention: Lachnosiraceae
Number of subjects: 492805
Study 33768223 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium
Number of subjects: 492805
Study 33768223 — intervention group
Group type: EXPERIMENTAL
Intervention: Prausnitzii
Number of subjects: 492805
Study 35742670 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergames physical activity training
Number of subjects: 48
Study 35742670 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical activity training
Number of subjects: 48
Study 32672329 — intervention group
Group type: EXPERIMENTAL
Intervention: Option Grids
Number of subjects: 237
Study 32672329 — intervention group
Group type: EXPERIMENTAL
Intervention: Shouldiscreen.com
Number of subjects: 237
Study 32544560 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost implant 10 μg
Number of subjects: 594
Study 32544560 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost implant 15 μg
Number of subjects: 594
Study 32544560 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5%
Number of subjects: 594
Study 35025538 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle medicine intervention (LMG; n = 39; eight weekly sessions)
Number of subjects: 79
Study 35025538 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (WLG; n = 40)
Number of subjects: 79
Study 34823552 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective Fostering Programme
Number of subjects: 0
Study 34823552 — intervention group
Group type: COMPARATOR
Intervention: Usual support
Number of subjects: 0
Study 32716479 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous EEG (cEEG) for 30 to 48 hours
Number of subjects: 364
Study 32716479 — intervention group
Group type: COMPARATOR
Intervention: Routine EEG (rEEG) - 2 sessions of 20 minutes each
Number of subjects: 364
Study 32716479 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous EEG (cEEG)
Number of subjects: 364
Study 35384257 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical probiotic-derived lotion
Number of subjects: 104
Study 35384257 — intervention group
Group type: COMPARATOR
Intervention: 2.5% benzoyl peroxide
Number of subjects: 104
Study 2012053242 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 240
Study 2012053242 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 240
Study 36057827 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamin supplementation (500μg methylcobalamin and 400μg folic acid once per day)
Number of subjects: 279
Study 36057827 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets once per day
Number of subjects: 279
Study 34033146 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance and impact training (HiRIT)
Number of subjects: 115
Study 34033146 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity exercise control (Buff Bones® [BB])
Number of subjects: 115
Study 34033146 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance and impact training (HiRIT) with antiresorptive medication
Number of subjects: 115
Study 34033146 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity exercise control (Buff Bones® [BB]) with antiresorptive medication
Number of subjects: 115
Study 33109643 — intervention group
Group type: EXPERIMENTAL
Intervention: CP@clinic (community paramedicine programme)
Number of subjects: 1461
Study 33109643 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1461
Study 35216547 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin (3.75 mg s.c. monthly for the first 3 months followed by 11.25 mg s.c. every 3 months)
Number of subjects: 36
Study 35216547 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (18 months)
Number of subjects: 36
Study 35216547 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin
Number of subjects: 36
Study 34618513 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher alliance quality
Number of subjects: 212
Study 34618513 — intervention group
Group type: EXPERIMENTAL
Intervention: More optimistic outcome expectation (OE)
Number of subjects: 212
Study 34618513 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists’ self-perceived alliance-fostering effectiveness
Number of subjects: 212
Study 34618513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive–behavioral orientation
Number of subjects: 212
Study 33744356 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg every 2 weeks
Number of subjects: 215
Study 33744356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 34623625 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat plus prior standard‐of‐care therapies (PSoCT)
Number of subjects: 1000
Study 34623625 — intervention group
Group type: COMPARATOR
Intervention: Prior standard‐of‐care therapies (PSoCT) alone
Number of subjects: 1000
Study 32418145 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 50
Study 32418145 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 50
Study 36058604 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual harassment policy training
Number of subjects: 0
Study 36058604 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 32794567 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily (BID)
Number of subjects: 0
Study 32794567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36102212 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib + Venetoclax
Number of subjects: 0
Study 36102212 — intervention group
Group type: COMPARATOR
Intervention: Venetoclax + Obinutuzumab
Number of subjects: 0
Study 32692358 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-α-lipoic acid (R-LA; 600 mg/d)
Number of subjects: 81
Study 35324262 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-focused Meatless Monday messages
Number of subjects: 1244
Study 35324262 — intervention group
Group type: EXPERIMENTAL
Intervention: Environment-focused Meatless Monday messages
Number of subjects: 1244
Study 35324262 — intervention group
Group type: COMPARATOR
Intervention: Control messages
Number of subjects: 1244
Study 33262411 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi‐pledget
Number of subjects: 179
Study 33262411 — intervention group
Group type: COMPARATOR
Intervention: Bipolar coagulation
Number of subjects: 179
Study 35254011 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrown
Number of subjects: 40
Study 35254011 — intervention group
Group type: COMPARATOR
Intervention: PCCR+post
Number of subjects: 40
Study 33231701 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 μg/day fluocinolone acetonide (FAc) intravitreal implant
Number of subjects: 324
Study 33475684 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX (fluorouracil, irinotecan, and oxaliplatin)
Number of subjects: 102
Study 33475684 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine/nab-paclitaxel
Number of subjects: 102
Study 33157330 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive photodynamic therapy (aPDT)
Number of subjects: 0
Study 33157330 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive antibiotic gel therapy (aAGT) (metronidazole 400 mg and amoxicillin 500 mg)
Number of subjects: 0
Study 33157330 — intervention group
Group type: COMPARATOR
Intervention: Mechanical debridement (MD) alone
Number of subjects: 0
Study 32928014 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (2mls, 8 mg) intravenously
Number of subjects: 192
Study 32928014 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo, 2mls) intravenously
Number of subjects: 192
Study 32734750 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise (3 sessions per week for 8 weeks)
Number of subjects: 60
Study 32734750 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 32989532 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot snare polypectomy (HSP)
Number of subjects: 272
Study 32989532 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic mucosal resection (EMR)
Number of subjects: 272
Study 33084406 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status assessment including hemoglobin and plasma retinol analysis
Number of subjects: 168
Study 33084406 — intervention group
Group type: EXPERIMENTAL
Intervention: Household food consumption and food insecurity assessment
Number of subjects: 168
Study 35289921 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSPER prevention delivery system implemented in middle schools
Number of subjects: 1985
Study 35289921 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 1985
Study 34431178 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 115
Study 34431178 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 115
Study 34010110 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week pilot intuitive eating intervention delivered through group and guided self-help
Number of subjects: 71
Study 34010110 — intervention group
Group type: EXPERIMENTAL
Intervention: Group modality
Number of subjects: 71
Study 34010110 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help modality
Number of subjects: 71
Study 34010110 — intervention group
Group type: EXPERIMENTAL
Intervention: Both modalities
Number of subjects: 71
Study 32877258 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour problem-solving, Story-bridge mental health literacy programme
Number of subjects: 0
Study 32877258 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33512629 — intervention group
Group type: EXPERIMENTAL
Intervention: Underbody blanket
Number of subjects: 99
Study 33512629 — intervention group
Group type: COMPARATOR
Intervention: Overbody blanket
Number of subjects: 99
Study 33382378 — intervention group
Group type: COMPARATOR
Intervention: Website (level 1)
Number of subjects: 202
Study 33382378 — intervention group
Group type: COMPARATOR
Intervention: Website and personalized diet and exercise prescription (level 2)
Number of subjects: 202
Study 33382378 — intervention group
Group type: COMPARATOR
Intervention: Website, personalized prescription, Fitbit, and text messages (level 3)
Number of subjects: 202
Study 33382378 — intervention group
Group type: EXPERIMENTAL
Intervention: Website, personalized prescription, Fitbit, text messages, and 2 phone calls (level 4)
Number of subjects: 202
Study 33382378 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 4 vs Level 1
Number of subjects: 202
Study 33382378 — intervention group
Group type: EXPERIMENTAL
Intervention: Website visit frequency
Number of subjects: 202
Study 33382378 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up rates
Number of subjects: 202
Study 36482844 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypopressive exercises
Number of subjects: 117
Study 36482844 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 117
Study 34418964 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital decision support system for GPs
Number of subjects: 13
Study 34418964 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication plans and discussions with GPs
Number of subjects: 13
Study 34418964 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare provider interactions
Number of subjects: 13
Study 34418964 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal experiences with medications
Number of subjects: 13
Study 34418964 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 13
Study 33086749 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 240 U
Number of subjects: 264
Study 33086749 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 360 U
Number of subjects: 264
Study 33086749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 35258115 — intervention group
Group type: EXPERIMENTAL
Intervention: CBLO-TTT
Number of subjects: 12
Study 35258115 — intervention group
Group type: COMPARATOR
Intervention: CBLO
Number of subjects: 12
Study 35258115 — intervention group
Group type: COMPARATOR
Intervention: TTT
Number of subjects: 12
Study 32228137 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert Feedback (EF)
Number of subjects: 36
Study 32228137 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert plus Help Screen (EF + HS)
Number of subjects: 36
Study 32228137 — intervention group
Group type: COMPARATOR
Intervention: Augmented visual (HS)
Number of subjects: 36
Study 35124615 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital group (CAD/CAM digital implant guide)
Number of subjects: 42
Study 35124615 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional impression)
Number of subjects: 42
Study 33486138 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-based brain training (n1 = 21)
Number of subjects: 41
Study 33486138 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (active control group, n2 = 20)
Number of subjects: 41
Study 36353274 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-MS (Salat after meals)
Number of subjects: 30
Study 36202649 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone replacement therapy
Number of subjects: 235
Study 36202649 — intervention group
Group type: COMPARATOR
Intervention: Hashimoto thyroiditis diagnosis
Number of subjects: 235
Study 36202649 — intervention group
Group type: COMPARATOR
Intervention: Multivariate analysis of Hashimoto thyroiditis
Number of subjects: 235
Study 35267967 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotic nutritional supplement (daily mixture of symbiotics, omega-3/6 fatty acids, and amino acids)
Number of subjects: 24
Study 35267967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32674103 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (SO) prior to NIV
Number of subjects: 380
Study 32674103 — intervention group
Group type: COMPARATOR
Intervention: No supplemental oxygen (SO) prior to NIV
Number of subjects: 380
Study 36309756 — intervention group
Group type: EXPERIMENTAL
Intervention: Gibbs Framework
Number of subjects: 0
Study 36309756 — intervention group
Group type: EXPERIMENTAL
Intervention: GRIPP-2(SF) checklist
Number of subjects: 0
Study 34161586 — intervention group
Group type: EXPERIMENTAL
Intervention: JUUL System (5.0% and 3.0% nicotine concentrations)
Number of subjects: 279
Study 34161586 — intervention group
Group type: EXPERIMENTAL
Intervention: JUUL System (Dual-Use group with 5.0% nicotine)
Number of subjects: 279
Study 34161586 — intervention group
Group type: COMPARATOR
Intervention: UB Cigarette group
Number of subjects: 279
Study 34161586 — intervention group
Group type: COMPARATOR
Intervention: Abstinence group
Number of subjects: 279
Study 32938569 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib
Number of subjects: 0
Study 32938569 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 0
Study 33683087 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical imiquimod 5% cream
Number of subjects: 103
Study 35745100 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Physical Activity (PA) group
Number of subjects: 57
Study 35745100 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Physical Activity (PA) group
Number of subjects: 57
Study 35745100 — intervention group
Group type: EXPERIMENTAL
Intervention: High Physical Activity (PA) group
Number of subjects: 57
Study 35745100 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 57
Study 33858395 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction for Teens (MBSR-T)
Number of subjects: 40
Study 33858395 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual Control (CTRL)
Number of subjects: 40
Study 32712173 — intervention group
Group type: EXPERIMENTAL
Intervention: 21% oxygen
Number of subjects: 22
Study 32712173 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 22
Study 34803132 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF treatment
Number of subjects: 40
Study 34803132 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly anti-VEGF injections
Number of subjects: 40
Study 34803132 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF every three months
Number of subjects: 40
Study 34411597 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-animal stabilized hyaluronic acid/dextranomer gel (Deflux; NASHA/Dx)
Number of subjects: 0
Study 32908192 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 506
Study 33543264 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-controlled diagnostic blocks
Number of subjects: 206
Study 33543264 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully randomized, placebo-controlled, triple blocks
Number of subjects: 206
Study 32975679 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg/day)
Number of subjects: 90
Study 32975679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 34042006 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected power and prescribed cadence of 80 revolutions per minute
Number of subjects: 24
Study 34042006 — intervention group
Group type: COMPARATOR
Intervention: Prescribed power of 100 W and self-selected cadence
Number of subjects: 24
Study 34236705 — intervention group
Group type: EXPERIMENTAL
Intervention: R15 method (three-pass, one-session procedure)
Number of subjects: 0
Study 34236705 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 0
Study 32739563 — intervention group
Group type: EXPERIMENTAL
Intervention: Question Prompt List (QPL)
Number of subjects: 71
Study 32739563 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 71
Study 32185417 — intervention group
Group type: EXPERIMENTAL
Intervention: Community participation programme based on the ecosystem model
Number of subjects: 1812
Study 32185417 — intervention group
Group type: COMPARATOR
Intervention: Usual official prevention programs (Control)
Number of subjects: 1812
Study 32185417 — intervention group
Group type: EXPERIMENTAL
Intervention: Community participation programme
Number of subjects: 1812
Study 33276944 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-experiencing polygenic risk score (PRS)
Number of subjects: 2030
Study 33276944 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure attachment style
Number of subjects: 2030
Study 33276944 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecure attachment style
Number of subjects: 2030
Study 33276944 — intervention group
Group type: EXPERIMENTAL
Intervention: PRS and attachment style interaction
Number of subjects: 2030
Study 33276944 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization analyses
Number of subjects: 2030
Study 33276944 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment style and IGSF11 gene variant (rs151177743)
Number of subjects: 2030